XNAS
DMAA
Market cap249mUSD
Jul 09, Last price
10.66USD
1D
-0.05%
1Q
1.33%
IPO
6.98%
Name
Drugs Made In America Acquisition Corp
Chart & Performance
P/E
—
P/S
—
EPS
0.25
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
6m
P
CFO
-539k
L+213.00%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate reorganizations.
Valuation
Title in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2025‑12 | 2024‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | ||
Unusual Expense (Income) | ||
NOPBT | ||
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | ||
Net income | ||
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | ||
BB yield | ||
| Debt | ||
Debt current | ||
Long-term debt | ||
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | ||
| Cash flow | ||
Cash from operating activities | ||
CAPEX | ||
Cash from investing activities | ||
Cash from financing activities | ||
FCF | ||
| Balance | ||
Cash | ||
Long term investments | ||
Excess cash | ||
Stockholders' equity | ||
Invested Capital | ||
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | ||
Price | ||
Market cap | ||
EV | ||
EBITDA | ||
EV/EBITDA | ||
Interest | ||
Interest/NOPBT |